Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + doxorubicin
- Development stage
- Phase 4
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + doxorubicin is an investigational combination regimen being developed for the neoadjuvant treatment of high-grade soft tissue sarcoma (STS). Anlotinib is a small-molecule, oral, multi-target tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptors (PDGFRα, PDGFRβ), and c-Kit, thereby exerting anti-angiogenic and anti-tumor effects. Doxorubicin is a small-molecule anthracycline antibiotic and cytotoxic chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. The combination is currently being evaluated in a single-arm, prospective clinical study (NCT05747521) at Henan Cancer Hospital, often in conjunction with radiotherapy, to assess its efficacy and safety as a pre-surgical treatment for patients with high-grade soft tissue sarcoma.
- Brand names
- Fukewei
- Other names
- anlotinib hydrochloride + doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)FGFR1 (Fibroblast growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on anlotinib + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + doxorubicin.